AGA Medical’s PREMIUM trial
This article was originally published in The Gray Sheet
Executive Summary
Firm initiates enrollment of its PREMIUM randomized trial to evaluate migraine reduction using its Amplatzer patent foramen ovale (PFO) occluder device, announced July 20. AGA expects to enroll 400 patients at up to 35 medical centers in the U.S. NMT similarly intends to focus on headache reduction following disappointing results from its U.K.-based MIST trial that showed the firm's STARflex PFO closure device to be no more effective than placebo in eliminating migraines entirely (1"The Gray Sheet" April 17, 2006, p. 9)...
You may also be interested in...
NMT Medical To Redesign PFO Trial After Problems With MIST I
NMT Medical will redesign its U.S. pivotal trial for the STARflex patent foramen ovale closure device to treat migraine headaches after its UK trial missed its primary endpoint
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.